Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial

BACKGROUND: The ARTemis trial previously reported that addition of neoadjuvant bevacizumab (Bev) to docetaxel (D) followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC) in HER2 negative breast cancer improved the pathological complete response (pCR) rate. We present disease-free survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Earl, H. M., Hiller, L., Dunn, J. A., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Gounaris, I., Abraham, J. E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartlett, J. M. S., Cameron, D. A., Provenzano, E., Thomas, J., Hayward, R. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834079/
https://www.ncbi.nlm.nih.gov/pubmed/28459938
http://dx.doi.org/10.1093/annonc/mdx173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834079/
https://www.ncbi.nlm.nih.gov/pubmed/28459938
http://dx.doi.org/10.1093/annonc/mdx173

Ejemplares similares